GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Pluristem Therapeutics Inc. (PSTI) [hlAlert]

Rating:
Buy PSTI
up 75.67 %

Pluristem Therapeutics Inc. (PSTI) rated Buy with price target $3 by Maxim Group

Posted on: Tuesday,  Dec 22, 2015  8:25 AM ET by Maxim Group

Maxim Group rated Buy Pluristem Therapeutics Inc. (NASDAQ: PSTI) on 12/22/2015, when the stock price was $1.11. Since
then, Pluristem Therapeutics Inc. has gained 75.68% as of 12/22/2015's recent price of $1.95.
If you would have followed this Maxim Group's recommendation on PSTI, you would have gained 75.67% of your investment in 0 days.

Pluristem Therapeutics Inc. is a bio-therapeutics company engaged in developing and intending to commercialize, cell therapy production technologies and products. The Company focuses on commercialization of non-personalized (allogeneic) cell therapy products for the treatment of several degenerative, ischemic and autoimmune disorders. It is developing a pipeline of products, stored ready to use, that are derived from human placenta, a non-controversial, non-embryonic adult stromal cell source. The Company?s focuses in the development of product candidates for local administration for indications, such as Peripheral artery disease (PAD), Critical limb ischemia (CLI), intermittent claudication, neuropathic pain, wound healing and orthopedic injuries. The Company focuses on developing Placenta expanded cells- peripheral artery disease (PLX-PAD) cells as an allogeneic therapeutic product to treat CLI which results from PAD.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
12/22/2015 8:25 AM Buy
None
1.11 3.00
as of 8/27/2015
1 Week down  -9.30 %
1 Month down  -26.41 %
3 Months down  -27.50 %
1 YTD down  -44.60 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/16/2013 10:25 AM Buy
None
3.45 8.00
6/4/2013 1:25 PM Hold
None
2.92
7/25/2012 10:25 AM Buy
None
3.34 8.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy